← Back to Clinical Trials
Recruiting NCT06507150

NCT06507150 AI-assisted Migraine Education: Efficacy, Safety and Patients' Acceptance

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06507150
Status Recruiting
Phase
Sponsor Ente Ospedaliero Cantonale, Bellinzona
Condition Migraine
Study Type INTERVENTIONAL
Enrollment 140 participants
Start Date 2024-09-01
Primary Completion 2027-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
AI-assisted migraine education (AIME)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 140 participants in total. It began in 2024-09-01 with a primary completion date of 2027-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Migraine affects 1 in 7 people globally, significantly impacting quality of life and economic productivity. Despite its prevalence, limited awareness leads to misdiagnosis, inadequate treatment, and stigmatization. AI can enhance migraine management through improved diagnosis, prediction, and personalized education. The primary objective of this study is to determine if adding AI-assisted migraine education to standard education improves patients' understanding of their condition more effectively.

Eligibility Criteria

Inclusion Criteria: * aged between 18 and 65 years at the time of signing the informed consent * Newly diagnosis of migraine, confirmed through the medical chart * The participant must be capable of giving signed informed consent * Access to a laptop, computer, smartphone, or tablet Exclusion Criteria: * Insufficient knowledge of the protocol language (italian) * Patients with cognitive impairment and/or unable to use or access the AI-powered learning platform developed in this study. * Vulnerable participants (e.g. minors, participants incapable of judgment or participants under tutelage)

Contact & Investigator

Central Contact

Giulia Mallucci, Prof. Dr.ssa med.

✉ giulia.mallucci@eoc.ch

📞 +41 91 811 69 21

Frequently Asked Questions

Who can join the NCT06507150 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Migraine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06507150 currently recruiting?

Yes, NCT06507150 is actively recruiting participants. Contact the research team at giulia.mallucci@eoc.ch for enrollment information.

Where is the NCT06507150 trial being conducted?

This trial is being conducted at Lugano, Switzerland.

Who is sponsoring the NCT06507150 clinical trial?

NCT06507150 is sponsored by Ente Ospedaliero Cantonale, Bellinzona. The trial plans to enroll 140 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology